172 related articles for article (PubMed ID: 9156267)
1. Gastro-intestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings.
Johansson JE; Ekman T
Bone Marrow Transplant; 1997 May; 19(9):921-5. PubMed ID: 9156267
[TBL] [Abstract][Full Text] [Related]
2. Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study.
Johansson JE; Ekman T
Bone Marrow Transplant; 1999 Jul; 24(1):35-9. PubMed ID: 10435732
[TBL] [Abstract][Full Text] [Related]
3. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
Johansson JE; Brune M; Ekman T
Bone Marrow Transplant; 2001 Oct; 28(8):737-42. PubMed ID: 11781624
[TBL] [Abstract][Full Text] [Related]
4. The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
Choi K; Lee SS; Oh SJ; Lim SY; Lim SY; Jeon WK; Oh TY; Kim JW
Clin Nutr; 2007 Feb; 26(1):57-62. PubMed ID: 16949180
[TBL] [Abstract][Full Text] [Related]
5. Gut protection by palifermin during autologous haematopoietic SCT.
Johansson JE; Hasséus B; Johansson P; Eklöf C; Ohman D; Stockelberg D
Bone Marrow Transplant; 2009 May; 43(10):807-11. PubMed ID: 19043460
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation.
Anderson PM; Ramsay NK; Shu XO; Rydholm N; Rogosheske J; Nicklow R; Weisdorf DJ; Skubitz KM
Bone Marrow Transplant; 1998 Aug; 22(4):339-44. PubMed ID: 9722068
[TBL] [Abstract][Full Text] [Related]
7. The role of biomedical and psychosocial factors for the prediction of pain and distress in patients undergoing high-dose therapy and BMT/PBSCT.
Schulz-Kindermann F; Hennings U; Ramm G; Zander AR; Hasenbring M
Bone Marrow Transplant; 2002 Feb; 29(4):341-51. PubMed ID: 11896432
[TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability.
Playford RJ; MacDonald CE; Calnan DP; Floyd DN; Podas T; Johnson W; Wicks AC; Bashir O; Marchbank T
Clin Sci (Lond); 2001 Jun; 100(6):627-33. PubMed ID: 11352778
[TBL] [Abstract][Full Text] [Related]
10. Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine).
Fazeny-Dörner B; Veitl M; Wenzel C; Brodowicz T; Zielinski C; Muhm M; Vogelsang H; Marosi C
Cancer Chemother Pharmacol; 2002 Apr; 49(4):294-8. PubMed ID: 11914908
[TBL] [Abstract][Full Text] [Related]
11. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial.
Jain PK; McNaught CE; Anderson AD; MacFie J; Mitchell CJ
Clin Nutr; 2004 Aug; 23(4):467-75. PubMed ID: 15297081
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
13. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?
Khoury H; Adkins D; Brown R; Trinkaus K; Vij R; Miller G; Goodnough LT; DiPersio J
Bone Marrow Transplant; 2000 Apr; 25(7):737-43. PubMed ID: 10745259
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Prince HM; Regester G; Gates P; Jablonskis L; Seymour JF; Lillie K; West R; Wolf M; Januszewicz H; Belford D
Biol Blood Marrow Transplant; 2005 Jul; 11(7):512-20. PubMed ID: 15983551
[TBL] [Abstract][Full Text] [Related]
15. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
17. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests.
Lutgens LC; Blijlevens NM; Deutz NE; Donnelly JP; Lambin P; de Pauw BE
Cancer; 2005 Jan; 103(1):191-9. PubMed ID: 15573372
[TBL] [Abstract][Full Text] [Related]
18. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
20. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
